In this week’s installment of highlighting investment opportunities, today, I’m going to cover ImmunoCellular Therapeutics (IMUC). Background ImmunoCellular Therapeutics is a California-based oncology firm with the lead candidate ICT-107 entering Phase II for patients with a particular form of brain cancer, glioblastoma multiforme (GBM). IMUC’s primary candidate targets cancer stem cells via a dendritic cell-based [...]

